Skip to main content

Table 1 Baseline characteristics of included studies

From: Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis

Authors (Year)

Language

Populations

Study design

Study period

NOS

Categories

No. samples

Mean age (Years)

Genders (Male/Female)

NIT (Yes/No)

Stages

CP features

Prognosis

Total

PE

NE

Boone et al. (2008) [38]

English

Netherland

ROS

1989–2006

7

✓

✗

105

26

79

62.0

56/49

None

I-IV

Chen et al. (2010) [39]

Chinese

China mainland

ROS

2006–2007

7

✓

✗

62

33

29

NI

NI

None

NI

Chuang et al. (2015) [40]

English

Taiwan

ROS

NI

8

✓

✓

75

39

36

57.0

72/3

54/21

I-IV

Hirashima et al. (2010) [41]

English

Japan

ROS

1996–2006

9

✓

✓

143

71

72

63.8

126/17

None

I-III

Hou et al. (2014) [42]

English

China mainland

ROS

NI

7

✓

✗

35

22

13

61.3

16/19

None

I-IV

Kim et al. (2013) [43]

English

Korea

ROS

1995–2008

8

✓

✓

165

74

91

NI

159/6

None

I-IV

Li et al. (2012) [44]

English

Taiwan

ROS

1999–2009

9

✗

✓

77

44

33

52.0

75/2

All received

I-III

Li et al. (2015) [45]

English

Taiwan

ROS

NI

8

✓

✓

105

59

46

54.0

103/2

None

I-IV

Lu et al. (2015) [46]

English

China mainland

ROS

2010–2012

8

✓

✓

148

94

54

59.0

114/34

None

I-III

  1. CP clinicopathological, CSS cancer-specific survival, DDE demographic data extrapolated, DFS disease-free survival, HR hazard ratio, IHC immunohistochemistry, M multivariate, NE negative expression, NI no information, NIT neo-adjuvant induction therapy, NOS Newcastle-Ottawa Scale, OR odds ratio, OS overall survival, PE positive expression, ROS retrospective observational study, U univariate